205 related articles for article (PubMed ID: 32959678)
21. Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation.
Kanji R; Vandenbriele C; Arachchillage DRJ; Price S; Gorog DA
Thromb Haemost; 2022 Apr; 122(4):480-491. PubMed ID: 33984868
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
Monteagudo-Vela M; Bowles C; Raj B; Robinson D; Simon A
Interact Cardiovasc Thorac Surg; 2022 Jan; 34(2):322-325. PubMed ID: 34849924
[TBL] [Abstract][Full Text] [Related]
23. Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO.
Streng AS; Delnoij TSR; Mulder MMG; Sels JWEM; Wetzels RJH; Verhezen PWM; Olie RH; Kooman JP; van Kuijk SMJ; Brandts L; Ten Cate H; Lorusso R; van der Horst ICC; van Bussel BCT; Henskens YMC
TH Open; 2020 Oct; 4(4):e365-e375. PubMed ID: 33235946
[No Abstract] [Full Text] [Related]
24. Heparin Monitoring with an Anti-Xa Protocol Compared to Activated Clotting Time in Patients on Temporary Mechanical Circulatory Support.
Feih JT; Wallskog KE; Rinka JRG; Juul JJ; Rein L; Gaglianello N; Baumann Kreuziger LM; Joyce DL; Tawil JN
Ann Pharmacother; 2022 May; 56(5):513-523. PubMed ID: 34423673
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic Modeling Using Real-World Data to Optimize Unfractionated Heparin Dosing in Pediatric Patients on Extracorporeal Membrane Oxygenation and Evaluate Target Achievement-Clinical Outcomes Relationship.
Salem AM; Smith T; Wilkes J; Bailly DK; Heyrend C; Profsky M; Yellepeddi VK; Gopalakrishnan M
J Clin Pharmacol; 2024 Jan; 64(1):30-44. PubMed ID: 37565528
[TBL] [Abstract][Full Text] [Related]
26. Anti-Xa-guided Anticoagulation With Unfractionated Heparin and Thrombosis During Extracorporeal Membrane Oxygenation Support: A Systematic Review and Meta-analysis.
Rajsic S; Breitkopf R; Treml B; Jadzic D; Innerhofer N; Eckhardt C; Oberleitner C; Nawabi F; Bukumiric Z
J Cardiothorac Vasc Anesth; 2024 Apr; ():. PubMed ID: 38839489
[TBL] [Abstract][Full Text] [Related]
27. Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study.
Cartwright B; Bruce HM; Kershaw G; Cai N; Othman J; Gattas D; Robson JL; Hayes S; Alicajic H; Hines A; Whyte A; Chaikittisilpa N; Southwood TJ; Forrest P; Totaro RJ; Bannon PG; Dunkley S; Chen VM; Dennis M
Sci Rep; 2021 Apr; 11(1):7975. PubMed ID: 33846433
[TBL] [Abstract][Full Text] [Related]
28. Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time.
Ahn HY; Jung Y; Kim TW; Cho YH; Yang JH; Chung CR; Min MS; Ko RE
Ann Pharmacother; 2024 Apr; 58(4):383-390. PubMed ID: 37401103
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis.
Swayngim R; Preslaski C; Burlew CC; Beyer J
Thromb Res; 2021 Dec; 208():18-25. PubMed ID: 34678527
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of thromboelastography in the management of anticoagulation for veno-venous extracorporeal membrane oxygenation in a coronavirus disease 2019 patient: A case report.
Nakashima R; Nishihara M; Iyonaga T; Iwasaka S; Yamamoto Y; Shono Y; Maki J; Tokuda K; Akahoshi T; Higo T; Kitazono T; Tsutsui H
Medicine (Baltimore); 2021 Jun; 100(23):e26313. PubMed ID: 34115042
[TBL] [Abstract][Full Text] [Related]
31. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment.
Balandina AN; Serebriyskiy II; Poletaev AV; Polokhov DM; Gracheva MA; Koltsova EM; Vardanyan DM; Taranenko IA; Krylov AY; Urnova ES; Lobastov KV; Chernyakov AV; Shulutko EM; Momot AP; Shulutko AM; Ataullakhanov FI
PLoS One; 2018; 13(6):e0199900. PubMed ID: 29953528
[TBL] [Abstract][Full Text] [Related]
32. The Heparin-Antithrombin Product: A Novel Value for Pediatric Extracorporeal Anticoagulation.
Rogerson CM; Hobson MJ
J Extra Corpor Technol; 2022 Jun; 54(2):115-122. PubMed ID: 35928336
[TBL] [Abstract][Full Text] [Related]
33. An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation.
Teng Y; Yan S; Liu G; Lou S; Zhang Y; Ji B
Front Med (Lausanne); 2022; 9():931863. PubMed ID: 35847800
[TBL] [Abstract][Full Text] [Related]
34. Varying Dosages of Subcutaneous Unfractionated Heparin and Activated Partial Thromboplastin Time in Hospitalized Antepartum Patients: A Retrospective Cohort Analysis.
Elmofty DH; Tucker A; Wuenstel AM; Cheng PK; Fox E; Knoebel R; Liao C; Scavone B
Anesth Analg; 2022 May; 134(5):1028-1034. PubMed ID: 35020621
[TBL] [Abstract][Full Text] [Related]
35. Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy.
Rhoades R; Leong R; Kopenitz J; Thoma B; McDermott L; Dovidio J; Barletti S; Gong JZ; Massey HT; McKenzie SE; Rame JE; Al-Rawas N
Thromb Res; 2021 Jul; 203():1-4. PubMed ID: 33894473
[No Abstract] [Full Text] [Related]
36. Satisfactory outcome with low activated clotting time in extracorporeal membrane oxygenation.
Hong JI; Hwang J; Shin HJ
Rev Cardiovasc Med; 2021 Dec; 22(4):1589-1594. PubMed ID: 34957799
[TBL] [Abstract][Full Text] [Related]
37. Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real-World Data: A Pharmacokinetic-Pharmacodynamic Modeling Approach.
Salem AM; Niu T; Li C; Moffett BS; Ivaturi V; Gopalakrishnan M
J Clin Pharmacol; 2022 Jun; 62(6):733-746. PubMed ID: 34816442
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of an aPTT guided versus a multimodal heparin monitoring approach in patients on extra corporeal membrane oxygenation: A retrospective cohort study.
Taha D; Drop JG; Wildschut ED; De Hoog M; van Ommen CH; Reis Miranda DD
Perfusion; 2024 May; ():2676591241253474. PubMed ID: 38739366
[TBL] [Abstract][Full Text] [Related]
39. Pseudo Heparin Resistance After Pulmonary Endarterectomy: Role of Thrombus Production of Factor VIII.
Nykänen AI; Selby R; McRae KM; Zhao Y; Asghar UM; Donahoe L; Granton J; de Perrot M
Semin Thorac Cardiovasc Surg; 2022; 34(1):315-323. PubMed ID: 33984481
[TBL] [Abstract][Full Text] [Related]
40. The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy.
Lapić I; Lončar Vrančić A; Coen Herak D; Rogić D
Biochem Med (Zagreb); 2021 Jun; 31(2):021003. PubMed ID: 34140837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
